Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Diabetes Free, Inc.

Clinicaltrial registered18 Nov 2026

Diabetes Free, Inc.

18 Nov 2026: Trial registered · Dual-targeting of B & T Cell Pathways Evaluation Trial. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
18 Nov 2026
Title
Dual-targeting of B & T Cell Pathways Evaluation Trial
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathies (IIM)
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Recruiting
Countries
Germany
Country
Germany
Reference
NCT07946367
Location
Germany
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Diabetes Free, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Germany

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.